In this review, we detail evidence supporting Lp(a) as a causal risk factor for ASCVD and AS/CAVD, and discuss approaches to managing Lp(a)-associated risk. The gene discussed is LPA; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.